Figure 1.

Rosiglitazone alleviates LPS‐induced pulmonary inflammatory responses in vivo. (A) Mice were pre‐treated with rosiglitazone (i.p., 0.1 mg·kg⁻¹) or vehicle and 1 h later treated with or without LPS (intra‐tracheally; 3 mg·kg⁻¹) for 16 h. H&E and immunohistochemical staining for ICAM‐1 and HO‐1 in serial sections of the lung tissues from Sham [0.1 mL of DMSO‐PBS (1:100) with 0.1% (W/V) BSA treated mice], LPS (LPS‐treated mice) and Rosi + LPS (rosiglitazone plus LPS mice). The arrows indicate the ICAM‐1 and HO‐1 expression on pulmonary alveolar cells. All images are representative of five mice per group. (B, C) Lung tissues were homogenized to extract protein and mRNA. The protein and mRNA levels of ICAM‐1 and HO‐1 were determined by Western blot and real‐time PCR. Data are expressed as mean ± SEM, from five independent experiments (n = 5). ^# P < 0.05, significantly different as indicated.